Toward understanding induction of oxidative stress and apoptosis by proteasome inhibitors
Guillem Paniagua Soriano1, Gerjan De Bruin, Herman S Overkleeft
1Gorlaeus Laboratories, Leiden Institute of Chemistry and Netherlands Proteomics Centre , Leiden, The Netherlands .
Significance:
Proteasome inhibitors (PIs) are used in the clinic for the treatment of hematopoietic malignancies. PI inhibitors induce endoplasmatic reticulum (ER) stress and oxidative stress, disruption of signaling pathways, mitochondrial dysfunction, and, eventually, cell death by apoptosis. PIs designated as clinical candidates include natural product derivatives and compounds developed by rational design and feature a wide diversity of structural elements. The vast amount of literature on this topic underscores PIs significance in driving basic research alongside therapeutic benefit.
Recent Advances:
Research in recent years has brought an in-depth insight into the molecular mechanisms of PI-induced apoptosis. However, there are some paradoxes and controversies in the literature. In this review, the advances and uncertainties, in particular on the time course events that make cells commit to apoptosis, are discussed. In addition, some mechanisms of evolved PI resistance are presented, and speculations on the difference in sensitivity between cell or tumor types are brought forward. The review concludes by giving an outlook of recent methods that may be employed to describe the system biology of how PIs impact cell survival decisions.
Critical Issues:
The biology of ER stress, reactive oxygen species (ROS) production, and apoptosis as induced by PIs is not well understood. Absorbed by the strong focus on PIs, one might overlook the importance of proteasome activity activators or modulators and the study of enzymatic pathways that lie up- or downstream from the proteasome function.
Future Directions:
An increased understanding of the systems biology at mRNA and protein levels and the kinetics behind the interaction between PIs and cells is imperative. The design and synthesis of subunit specific inhibitors for each of the seven known proteasome activities and for the enzymes associated to proteasomes will aid in unraveling biology of the ubiquitin-proteasome system in relation to ER stress, ROS production, and apoptosis and will generate leads for therapeutic intervention.
Insights
Proteasome inhibitors (PIs) are crucial for treating blood cancers by inducing cell death. Further research into their complex mechanisms and resistance is needed for improved cancer therapies.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Cellular Stress Responses
Background:
- Proteasome inhibitors (PIs) are established treatments for hematopoietic malignancies.
- PIs induce endoplasmic reticulum (ER) stress, oxidative stress, and apoptosis.
- Recent research offers insights into PI-induced apoptosis mechanisms, but paradoxes remain.
Purpose of the Study:
- To review advances and uncertainties in PI-induced apoptosis.
- To discuss mechanisms of PI resistance and differential sensitivity.
- To explore systems biology approaches for understanding PI effects on cell survival.
Main Methods:
- Literature review of proteasome inhibitor mechanisms.
- Analysis of ER stress, oxidative stress, and apoptosis pathways.
- Discussion of systems biology and omics-level analyses.
Main Results:
- The precise biology of ER stress, ROS production, and apoptosis induced by PIs is not fully understood.
- Focus on PIs may overshadow the importance of proteasome activators and associated enzymatic pathways.
- Controversies exist regarding the temporal events leading to apoptosis commitment.
Conclusions:
- Deeper understanding of systems biology, including mRNA and protein levels, is essential.
- Developing subunit-specific proteasome inhibitors could elucidate ubiquitin-proteasome system biology.
- Targeting proteasome-associated enzymes may yield new therapeutic strategies for cancer treatment.
Related Concept Videos
Cellular Injury V: Apoptosis and Autophagy
The Intrinsic Apoptotic Pathway
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulation of the Unfolded Protein Response
Apoptosis


